With FY2016 numbers much in-line with our expectations, MDxHealth is becoming a leader in diagnosis of prostate and other urological cancers. Its lead product ConfirmMDx reducing the need for unnecessary biopsies continues to grow as it is increasingly adopted by US urologists and reimbursed by public and private payers. Its first urine-based biopsy SelectMDx is gaining traction through MDxHealth's existing laboratory and commercial platform. The anticipated launch of an IVD SelectMDx kit for Eu ....
24 Feb 2017
Further growth and catalysts in 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further growth and catalysts in 2017
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
24 Feb 2017 -
Author:
Chris Redhead -
Pages:
11
With FY2016 numbers much in-line with our expectations, MDxHealth is becoming a leader in diagnosis of prostate and other urological cancers. Its lead product ConfirmMDx reducing the need for unnecessary biopsies continues to grow as it is increasingly adopted by US urologists and reimbursed by public and private payers. Its first urine-based biopsy SelectMDx is gaining traction through MDxHealth's existing laboratory and commercial platform. The anticipated launch of an IVD SelectMDx kit for Eu ....